CELL INTELLIGENCE · 肿瘤细胞治疗研究

细胞外 ATP-P2RY2 信号驱动瘤内前列腺素 E2 蓄积及实体瘤免疫治疗适应性耐药

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors.

利用肿瘤微环境增强工程化淋巴细胞过继 T 细胞疗法治疗实体瘤

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors.

识别人类间皮素的人类白细胞抗原非依赖性 T 细胞受体的筛选、工程化改造及体内测试

Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin.

HiT 可以从针对细胞表面表达抗原的全人 TCR 展示噬菌体库中分离得到。HiT 能够在体内和体外完全激活原代 T 细胞。HiT 可能使 pHLA 靶向 TCR 在实体瘤中观察到的疗效得以转化应用于细胞表面抗原。

工程化双特异性γδ T 细胞受体用于癌症免疫治疗

Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy.

用于 T 细胞过继免疫治疗的体外扩增过程中产生的非典型 T 细胞表征

Characterization of atypical T cells generated during ex vivo expansion process for T cell-based adoptive immunotherapy.

IQ 联盟对 CAR-T 与 TCR-T 细胞疗法开发生物分析及免疫原性评估最佳实践的观点

An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Developme

通过创新实现的进化作为改善 TCR-T 疗法的驱动力

Evolution by innovation as a driving force to improve TCR-T therapies.

基因工程化 CAR-T 与 TCR-T 细胞制备与应用的当前与未来理念

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.

实体瘤中的 TCR 工程化 T 细胞治疗：现状与展望

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.

肿瘤负荷和抗原特异性 T 细胞数量是癌症疫苗和 TCR 工程 T 细胞治疗临床反应的主要参数

Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell thera

我们提出，治疗性疫苗应考虑用于低或中等肿瘤负荷的情况，而 Tg-T 细胞策略可能更适合晚期转移性疾病的治疗。